ASX:BB1Health Care Equipment & ServicesHealth Care Technology
BlinkLab Ltd
$0.860
$0.010 (1.15%)
Day Range
$0.850 – $0.875
52 Week Range
$0.500 – $1.105
Volume
144.66K
Avg Volume (10D)
412.00K
Market Cap
$131.80M
Price Chart
OHLC · volume · moving averages
$0.860-$0.068 (-7.28%)over 6M
Hi$0.953Lo$0.560Avg Vol196.3K
Price-sensitive newsVolumePrev close · 52W rangeDrag the handles below to zoom
Market Statistics
Today's trading range
Open
$0.870
Previous Close
$0.870
Day High
$0.875
Day Low
$0.850
52 Week High
$1.105
52 Week Low
$0.500
Valuation
Fundamental multiples
Market Cap
131.80M
Shares Outstanding
153.26M
Price to Book
6.94
Trading Activity
Volume & order book
Volume
144.66K
Value Traded
124.61K
Bid
$0.855 × 10,840
Ask
$0.860 × 23,947
Performance
Returns across timeframes
1 Day
-2.21%
5 Day
32.09%
13 Week
22.92%
52 Week
80.61%
YTD
9.26%
Technical Indicators
Momentum & moving averages
RSI (14)
65.37
50-Day SMA
$0.673
200-Day SMA
$0.775
— From the desk
Latest News
Biotechnology
BlinkLab Reports Positive ADHD Assessment Results from European Dx2 Diagnostic Platform Study
BlinkLab reports ADHD Dx2 results: 82% sensitivity, 83% specificity in European study, signaling new smartphone-based diagnostic tool.
Biotechnology
BlinkLab Raises A$17.5m to Fund FDA Autism Diagnostic Clearance and Advance ADHD Trials
BlinkLab raises oversubscribed A$17.5m to push FDA autism Dx1 clearance and start ADHD Dx2 trials; Morocco rollout underpins real-world data.
Biotechnology
BlinkLab Commences Pivotal FDA 510(k) Validation Program with First Participant Enrolment
BlinkLab kicks off pivotal FDA 510(k) validation for Dx1 autism diagnostic aid; first participant enrolled as an 8-month study targeting end-2026 submission.
Biotechnology
BlinkLab Completes Pivotal FDA Study Site Network Ahead of Q1 2026 Trial Start
BlinkLab completes 10-site pivotal FDA study network ahead of March 2026 start; pilot 83.7%/84.7%; 510(k) submission H2 CY2026.